Trial · NCT07884110
Liver Transplantation for Colorectal Cancer
NCT07884110, Recruiting, Pontificia Universidad Catolica de Chile
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Liver Transplantation for Colorectal Cancer. Trials, record NCT07884110. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884110
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Liver Transplantation for Colorectal Cancer
- NCT number
- NCT07884110
- Status
- Recruiting
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Pontificia Universidad Catolica de Chile
- Conditions
- Colorectal Cancer, Liver Metastasis
- Interventions
- Liver transplantation
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | Up to 5 years after liver transplantation | Time from liver transplant to death from any cause, among patients who underwent liver transplantation (as-treated/per-protocol population). |
| Secondary | Recurrence-Free Survival (RFS), Per-Protocol | Up to 5 years after liver transplantation | Time from liver transplant to first documented radiographic recurrence or death from any cause, whichever occurs first, among patients who underwent liver transplantation (as-treated/per-protocol population). |
| Secondary | Recurrence-Free Survival (RFS), Intention-to-Treat | Up to 5 years from committee approval | Time from liver transplant to first documented radiographic recurrence or death from any cause, whichever occurs first, among patients whose transplant was approved by the UC Liver Transplant Committee (intention-to-treat population). |
| Secondary | Overall Survival (OS), Intention-to-Treat | Up to 5 years from committee approval | Time from liver transplant to death from any cause, among patients whose transplant was approved by the UC Liver Transplant Committee (intention-to-treat population). |
| Secondary | Safety of Liver Transplantation | At 30 days, 90 days, and 1 year after liver transplantation | Incidence and severity of perioperative and postoperative complications, classified according to the Clavien-Dindo classification and CTCAE version 5.0, and coded by preferred term and organ class using the most recent version of MedDRA. Safety of living liver donors is also assessed. |
| Secondary | Health-Related Quality of Life (EORTC QLQ-C30) | At selection, 1 month before transplant, 3 months, 6 months, and at disease progression, up to 5 years | Change in health-related quality of life assessed with the EORTC QLQ-C30, a validated 30-item structured questionnaire designed to evaluate quality of life in cancer patients. |
| Secondary | Correlation of Molecular Tumor Markers With Clinical Outcomes | Up to 5 years after liver transplantation | Correlation of molecular marker expression (RAS, BRAF, HER2, and microsatellite instability \[MSI\]), assessed by immunohistochemistry or gene expression by next-generation sequencing (NGS) in primary tumor biopsy and liver explant specimens, with clinical outcomes. |
| Secondary | Correlation of Serologic and Inflammatory Biomarkers With Clinical Outcomes | Up to 5 years after liver transplantation | Correlation of tumor marker expression (carcinoembryonic antigen \[CEA\]), inflammatory parameters (neutrophil-to-lymphocyte ratio \[NLR\] and lymphocyte counts), C-reactive protein (CRP), and minimal residual disease testing in peripheral blood or plasma with clinical outcomes. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884110
GET https://conductscience.org/api/trials/v1/NCT07884110/registered